Fig 1.
Clinical, genetic and molecular characteristics in (A) secondary high-grade glioma and (B) pediatric low-grade glioma (PLGG) undergoing transformation. Frequency of genetic or molecular alterations indicated as percentage at the far right of each row. AA, anaplastic astrocytoma; AGG, anaplastic ganglioglioma; APXA, anaplastic pleomorphic xanthoastrocytoma; bMMRD, biallelic mismatch repair deficiency syndrome; CPS, cancer predisposition syndrome; Dx, diagnosis; GBM, glioblastoma; GG, ganglioglioma; HG, high grade; LFS, Li-Fraumeni syndrome; LG, low grade; LGA, low-grade astrocytoma; MT, malignant transformation; N/A, not applicable; PA, pilocytic astrocytoma; PXA, pleomorphic xanthoastrocytoma; RT, radiotherapy. p53 dysfunction is defined by more than 50% p53 immunopositive tumor cells and/or TP53 mutation.